RxDoctor Payments Data

Madison Wesseln, PA

Physician Assistant · Rancho Mirage, CANPI 1215554258

Payments from drug & device makers

$1,906in general payments, 2019–2025

Across 52 payments — averaging $36.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$634
  • AbbVie$372
  • Johnson & Johnson$280
  • Bayer$125
  • Redhill Biopharma Inc.$110
  • Collegium Pharmaceutical, Inc.$94
  • plus $290 from 9 others

What the payments were for

  • Food & beverage$1,89299%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,906 in reported general payments places this provider in the 80th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$90,690
Medicare patients
589
Services billed
1,299

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban66$88,098
JardianceEmpagliflozin60$76,159
XareltoRivaroxaban36$37,302
EntrestoSacubitril/Valsartan21$31,006
OzempicSemaglutide11$17,850
Rosuvastatin Calcium90$1,331
Metoprolol Succinate65$1,168
Ezetimibe28$816
Amlodipine Besylate105$768
Losartan Potassium45$496
Levothyroxine Sodium49$464
Atorvastatin Calcium33$417
Potassium Chloride20$404
Carvedilol35$321
Olmesartan Medoxomil11$251

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$280$37,30236 claims
Novo NordiskOzempic$51$17,85011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,423 physician assistant providers in California.

Other physician assistant in Rancho Mirage

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →